MedTrace Logo

Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer

NCT01732939 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2014-02-19

No results posted yet for this study

Summary

The study purpose is to observe which neoadjuvant chemotherapy regimens is the better for invasive breast cancer. The neoadjuvant chemotherapy regimen is sustained anthracyclines plus taxanes or from anthracyclines plus taxanes to vinorelbine plus cisplatinum.

Conditions

Sponsors & Collaborators

  • Hospital Affiliated to Military Medical Science, Beijing

    lead OTHER

Principal Investigators

  • Zefei Jiang, MD · Hospital Affiliated Military Medical Science

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-12-31
Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01732939 on ClinicalTrials.gov